Novartis Announced Results From The Phase Ii Open-Label Extension Orion-3 Trial, Which Showed That Leqvio Provides Effective Low-Density Lipoprotein Cholesterol (Ldl-C) Reduction Over A Four-Year Period In Patients With Either Atherosclerotic Cardiovascular Disease (Ascvd) Or Ascvd Risk Equivalent, And Elevated Ldl-C Despite Maximally Tolerated Statin Therapy. Leqvio Is The First And Only Small Interfering Rna (Sirna) Therapy To Lower Ldl-C And Is Administered With Two Doses A Year. Results Were Presented At The American Heart Association (Aha) Scientific Sessions 2022.
